Myositis

Myositis (Idiopathic Inflammatory Myopathy, IIM) are auto-immune diseases related to muscles. They are not hereditary. They are characterized by a muscle weakness and fatigability, and very often by muscle pain (myalgia).

 

Clinical trials ongoing at the Institute:

  • ADSVF-in-IBM: Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial
  • IgPro20_3007: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM)
  • RA101495-02.202: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy (IMNM)
  • BMS-188667: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)

 

Acronym

ADSVF-in-IBM

IgPro20_3007

RA101495-02.202

BMS-188667

Study type RIPH1 RIPH1 RIPH1 RIPH1
Intervention Cell therapy Hizentra Zilucoplan
Principal investigator Olivier Benveniste Olivier Benveniste Olivier Benveniste Olivier Benveniste
Sponsor APHP CSL Behring RAPharma Bristol-Myers Squibb
Fundings PHRC CSL Behring RAPharma Bristol-Myers Squibb
Pathology IBM DM IMNM IIM
Study status In preparation In preparation In preparation Ongoing
Recruitment status In preparation In preparation In preparation Ongoing
Population Adult Adult Adult Adult
+ infos on clinicaltrials.gov + infos on clinicaltrials.gov + infos on clinicaltrials.gov